<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701831</url>
  </required_header>
  <id_info>
    <org_study_id>LANTU_L_03502</org_study_id>
    <nct_id>NCT00701831</nct_id>
  </id_info>
  <brief_title>Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control</brief_title>
  <acronym>LANTIT</acronym>
  <official_title>Assessment of Forced Titration to Reach the Effective Dose for Good Glycemic Control in Lantus Treated Type 2 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:

        -  To observe the efficacy of the forced titration to reach good glycemic control in Lantus
           treated patients

      Secondary objectives:

        -  To assess the forced titration on physician and patient satisfaction

        -  To evaluate the impact of training tools by means of patient profile
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c, FBG</measure>
    <time_frame>after treatment end (6 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Final dose</measure>
    <time_frame>after treatment end (6 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of dose adjustment</measure>
    <time_frame>after treatment end (6 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to dose titration</measure>
    <time_frame>after treatment end (6 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>after treatment end (6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Noctural hypoglycemia</measure>
    <time_frame>after treatment end (6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DTSQ</measure>
    <time_frame>after treatment end (6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Satisfaction Questionnaire</measure>
    <time_frame>after treatment end (6 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">241</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin glargine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
    <description>The dose is titrated according to patient needs</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  T2 insulin na√Øve patients

          -  Patients whom their physician is considering initiation of Lantus treatment

          -  Poor glycemic control 7,5 %10 %

          -  T2 treatment with OADs more than 3 months

          -  BMI&lt;40 kg/m2

        Exclusion Criteria:

          -  Impaired renal function (Cr&gt;2mg/dl or current renal dialysis)

          -  Acute or chronic metabolic acidosis

          -  Active liver disease or serum ALT or AST &gt;2,5 than normal

          -  History of hypoglycemia unawareness

          -  Diabetic retinopathy with surgery in the previous 3 months or planned within 3 months
             after study entry

          -  Pregnancy, breast feeding

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zeynep Cetin</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>November 3, 2010</last_update_submitted>
  <last_update_submitted_qc>November 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Trial Transparency Team</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

